Rapid metabolizer genotype of CYP 2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis - Ichikawa, H; Sugimoto, M; Sugimoto, K (J Gastroenterol Hepatol, 2016)